Updated:
Keren Keshet - The Rainbow Foundation
Keren Keshet - The Rainbow Foundation was established in 1999 by financier Zalman Chaim Bernstein, the founder of Sanford C. Bernstein & Co., and is currently...
Keren Keshet - The Rainbow Foundation
Keren Keshet - The Rainbow Foundation was established in 1999 by financier Zalman Chaim Bernstein, the founder of Sanford C. Bernstein & Co., and is currently led by his widow, Mem Dryan Bernstein. The foundation's corpus originates from the sale proceeds of the Bernstein research and investment management firm, which built a reputation for rigorous, independent equity analysis on Wall Street. The foundation operates as a private philanthropy, distinct in structure from the better-known AVI CHAI Foundation, which Zalman Bernstein also endowed. Keren Keshet deploys capital across two distinct tracks. Its grant-making arm supports Jewish educational and cultural programs, focusing on cultivating Jewish leadership in the United States, Israel, and the former Soviet Union. In parallel, the foundation pursues a direct buyout investment strategy, allocating to private Israeli companies. Confirmed positions have included healthcare and biotech ventures such as BrainsWay, a neurostimulation device company, where the foundation invested alongside prominent co-investor Michael Steinhardt. The geographic footprint of its mission-driven capital centers on New York, Jerusalem, and communities across the former Soviet Union. The foundation maintains a lean operational profile managed from New York, with trustees including longtime Bernstein advisor Arthur W. Fried. Its known real asset holdings include a commercial property at 1210 Scott Street in San Francisco, home to the Jewish Community High School of the Bay, and participation in the Metropolitan Museum of Art's Acquisition Fund. The foundation is a member of Philanthropy New York, the regional association of grantmakers. In recent years, the philanthropic side of the enterprise has continued its quiet support of initiatives that strengthen Jewish identity, reflecting the founder's stated lifelong commitment to the Jewish people. The foundation's dual mandate — direct private-equity-style investment in Israeli industry paired with traditional grant-making to Jewish nonprofits — sets it apart from most endowed philanthropies. Rather than outsourcing the endowment to external managers and focusing solely on charitable distributions, Keren Keshet actively participates in buyout rounds, aligning its investment activity with a broader mission to support Israel's economic and technological development. This blended model, governed by a tight group of trustees closely linked to the founder, makes its capital both philanthropic and catalytic.
General information
Firm type
Endowment / Foundation
Year founded
1999
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Mem Dryan Bernstein
President and Trustee
Zalman Chaim Bernstein
Founder and Benefactor
Arthur W. Fried
Trustee
Sector focus
Frequently asked questions
How does Keren Keshet's investment activity relate to its philanthropic mission?
The foundation pursues a dual mandate. Its grant-making arm funds Jewish educational and cultural leadership programs globally, while its investment arm makes direct buyout investments, primarily in Israeli technology and healthcare companies. This approach aligns the foundation's capital allocation with a goal of strengthening Israel's economic infrastructure, alongside more traditional charitable giving.
Who runs investment decisions at Keren Keshet?
President and Trustee Mem Dryan Bernstein oversees the foundation's activities. The investment and grant-making decisions are made under the governance of a small board of trustees that has historically included Arthur W. Fried, a longtime advisor to founder Zalman Bernstein. The foundation does not employ a large in-house investment staff, relying on its tight-knit leadership.
What is the relationship between Keren Keshet and the AVI CHAI Foundation?
Both foundations were endowed by Zalman Chaim Bernstein and share a commitment to Jewish education and continuity. AVI CHAI was the larger and more prominent vehicle, known for its structured spend-down strategy, which concluded operations around 2019. Keren Keshet operates as a separate, ongoing private foundation with a distinct, less public profile.
Does Keren Keshet participate in fund commitments or only direct deals?
The foundation's primary investment strategy is categorized as direct buyouts, rather than commitments to external private equity funds. It has participated directly in financing rounds for operating companies, as evidenced by its investment in BrainsWay alongside co-investors. There is no public record of the foundation acting as a limited partner in commingled funds.
What kind of healthcare investments has Keren Keshet made?
The foundation has directly invested in Israeli health-tech and biotech ventures. One publicly confirmed position is BrainsWay, a company that developed and commercialized Deep Transcranial Magnetic Stimulation (Deep TMS) technology for treating neuropsychiatric disorders. The investment was made in partnership with notable investor Michael Steinhardt.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: